Core Insights - The article highlights the growing collaboration between Changsha and Africa in the pharmaceutical industry, emphasizing the potential for mutual growth and development in healthcare solutions [1][2][3]. Group 1: Market Expansion - Changsha-based companies are actively entering the African pharmaceutical market, with SinoCare's blood glucose monitors being distributed to over 40 African countries, and sales expected to reach 160 million yuan by 2026 [2][3]. - The medical technology company Kaimaisen has gained attention at international conferences, showcasing its gynecological solutions and initiating technology transfer discussions with multiple countries [1][2]. - The establishment of a comprehensive intervention and imaging center in Nigeria, with an initial investment of 5 million USD, aims to address the healthcare needs of cardiovascular patients [3]. Group 2: Local Production and Innovation - Companies like Erkang Pharmaceutical are investing in local production facilities in Africa, focusing on lithium carbonate production and GMP-compliant drug manufacturing to meet local healthcare demands [4][5]. - The introduction of training programs for local healthcare professionals, such as the gynecological minimally invasive training project, is enhancing local medical capabilities [5][6]. Group 3: Trade and Economic Growth - Changsha's trade with Africa has seen significant growth, with imports and exports reaching 8.88 billion yuan in the first four months of the year, marking a 74.2% increase year-on-year [6][7]. - The establishment of logistics routes, including direct shipping lines to Kenya and Ethiopia, is facilitating faster delivery of goods, enhancing trade efficiency [6][7]. Group 4: Policy Support and Infrastructure - The Hunan government has introduced policies to support deepened cooperation with Africa, including the establishment of public overseas warehouses and inspection laboratories to streamline trade processes [6][7]. - The creation of the Changsha Africa Economic and Trade Headquarters Base is attracting numerous enterprises and organizations, fostering a diverse industrial cluster focused on African markets [5][6]. Group 5: Future Prospects - The upcoming fourth China-Africa Economic and Trade Expo will feature various trade activities aimed at enhancing cooperation across multiple sectors, including healthcare, infrastructure, and cultural exchange [7]. - Changsha's commitment to building a health connection between China and Africa is expected to lead to more collaborative projects, enhancing local production capabilities and reducing dependency on imports [7].

Company Overview - Sanofi Bio reported a closing price of 20.93 yuan as of June 6, 2025, down 1.97% from the previous week's 21.35 yuan [1] - The company's market capitalization is currently 11.81 billion yuan, ranking 24th out of 126 in the medical device sector and 1334th out of 5148 in the A-share market [1] Key Announcements - Sanofi Bio will suspend the conversion of "Sanofi Convertible Bonds" from June 5, 2025, until the record date for the current equity distribution, with the conversion price adjusted from 34.61 yuan to 34.39 yuan per share [1][3] - The 2024 annual equity distribution plan includes a cash dividend of 2.20 yuan per 10 shares (tax included), with the ex-dividend date set for June 13, 2025 [1][3] - The maximum repurchase price for shares has been adjusted from 34.00 yuan to 33.78 yuan, effective from June 13, 2025 [1][3]

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-054 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 重要内容提示： 1、调整前回购股份价格上限：不超过人民币34.00元/股（含） 2、调整后回购股份价格上限：不超过人民币33.78元/股（含） 三诺生物传感股份有限公司 关于2024年年度权益分派实施后调整回购股份 价格上限的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据公司《关于回购公司部分股份方案暨取得金融机构股票回购专项贷款承 诺函的公告》《回购股份报告书》的相关约定，自公司董事会通过本次回购股份 方案之日起至回购实施完成前，若公司实施送股、资本公积转增股本、现金分红、 配股、股票拆细、缩股及其他等除权除息事项，自股价除权除息之日起，按照中 国证监会及深圳证券交易所的相关规定相应调整回购股份价格上限。 公司于2025年5月14日召开2024年年度股东大会，审议并通过《关于<公司 2024年度利润分配预案>的议案》。公司2024年年度权益分派方案为：以公司实 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-053 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 派送股票股利或转增股本：P1=P0/（1+n）； 关于可转换公司债券转股价格调整的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 一、关于可转换公司债券转股价格调整的相关规定 经中国证券监督管理委员会（以下简称"中国证监会"）《关于三诺生物股 份有限公司公开发行可转换公司债券的批复》（证监许可〔2020〕2951号）核准， 三诺生物传感股份有限公司（以下简称"公司"）于2020年12月21日向不特定对 象共发行500.00万张可转换公司债券，每张面值人民币100元，发行总额50,000.00 万元，本次可转换公司债券已于2021年1月12日起在深交所挂牌交易。债券简称 "三诺转债"，债券代码"123090"。三诺转债初始转股价格为35.35元/股。 根据《三诺生物传感股份有限公司创业板向不特定对象发行可转换公司债券 募集说明书》（以 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-052 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 1、公司2024年年度股东大会审议通过的2024年度利润分配方案如下：以公 司未来实施2024年度利润分配方案时股权登记日的总股本剔除因公司通过集中 竞价交易方式回购的、依法不参与利润分配的股份之后的股本总额为基数，向全 体股东每10股派发现金股利2.20元人民币（含税）。本次利润分配不送红股，不 进行资本公积金转增股本，剩余未分配利润结转下一年度。在本次利润分配方案 披露日至实施权益分派股权登记日期间，公司股本总额若因股权激励行权、股份 回购、可转债转股等事项发生变化，公司将维持每股分配比例不变，相应调整分 配总额。 特别提示： 1、三诺生物传感股份有限公司（以下简称"公司"）2024年年度权益分派 方案为：以公司实施2024年度利润分配方案时股权登记日的总股本，剔除因 ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-050 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于回购公司部分股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）于 2025 年 2 月 20 日召开 第五届董事会第十六次会议和第五届监事会第十二次会议，审议并通过《关于回 购公司部分股份方案的议案》，同意公司使用自有资金及银行回购专项贷款以集 中竞价交易的方式回购公司部分社会公众股份，用于员工持股计划、股权激励或 者用于转换上市公司发行的可转换为股票的公司债券。回购资金总额不低于人民 币 15,000 万元且不超过人民币 30,000 万元（均含本数），回购价格不超过人民币 34.00 元/股（含），实施期限为自董事会审议通过本次回购部分股份方案之日起 12 个月内。回购事项具体内容详见公司分别于 2025 年 2 月 20 日、2025 年 2 月 24 日在巨潮资讯网（www.cni ...

| 证券代码：300298 | 证券简称：三诺生物 | 公告编号：2025-051 | | --- | --- | --- | | 债券代码：123090 | 债券简称：三诺转债 | | 三诺生物传感股份有限公司 关于权益分派期间三诺转债暂停转股的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 三诺生物传感股份有限公司（以下简称"公司"）将于近日实施2024年年度 权益分派，根据《三诺生物传感股份有限公司创业板向不特定对象发行可转换公 司债券募集说明书》中关于"转股价格的调整及计算方式"条款的规定（详见附 件）及《深圳证券交易所创业板上市公司自律监管指南第1号——业务办理》等 相关规定，自2025年6月5日至本次权益分派股权登记日止，公司可转换公司债券 （债券代码：123090；债券简称：三诺转债）将暂停转股，本次权益分派股权登 记日后的第一个交易日起恢复转股。 在上述暂停转股期间，公司可转换公司债券"三诺转债"可正常交易，敬请 债券持有人留意。 特此公告。 三诺生物传感股份有限公司董事会 附件： 《三诺生物传感股份有限公司创业板向不特 ...

Group 1 - The 12th Overseas Returnees Forum held a talent recruitment event in Changsha, featuring over 50 leading companies offering more than 500 positions, with some roles offering annual salaries up to 800,000 yuan [1][3] - SANY Group reported an overseas revenue of 58.3 billion yuan in 2024 and emphasized the strong demand for international talent in key areas such as smart manufacturing and global supply chain management [3] - Anker Innovations, a major global smart hardware brand, continues to expand its business and has a growing need for overseas talent, with 90% of its business being international [3] Group 2 - The recruitment event attracted over 160 job seekers, and the organizing committee plans to hold a series of specialized recruitment activities to connect overseas returnees with companies [4] - Companies are customizing job positions based on the expertise of job seekers, which is seen as beneficial for the growth of young professionals [4] - The event serves as a platform to encourage more overseas returnees to participate in initiatives aimed at boosting local talent and innovation [4]

关于第二期员工持股计划第四个锁定期届满的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 三诺生物传感股份有限公司（以下简称"公司"）分别于 2021 年 4 月 15 日、 2021 年 5 月 10 日召开第四届董事会第十四次会议、2020 年年度股东大会，审议 并通过《关于<三诺生物传感股份有限公司第二期员工持股计划（草案）>及其摘 要的议案》以及《关于提请股东大会授权董事会办理第二期员工持股计划相关事 宜的议案》，同意授权公司董事会办理公司第二期员工持股计划的相关具体事宜； 公司于 2021 年 5 月 26 日召开第四届董事会第十五次会议，审议并通过《关于< 三诺生物传感股份有限公司第二期员工持股计划（草案修订稿）>及其摘要的议 案》和《关于<三诺生物传感股份有限公司第二期员工持股计划管理办法（修订 稿）>的议案》，同意公司根据《公司法》《证券法》《关于上市公司实施员工持股 计划试点的指导意见》等相关法律、行政法规、规范性文件以及《公司章程》的 有关规定，并结合公司实际情况，对《三诺生物传感股份有限公司第二期员工持 股计划（草案）及其摘要》 ...

Group 1 - The company announced the repurchase of its convertible bonds, allowing holders to sell back their bonds at a price of RMB 100.735 per bond during the specified period from May 19 to May 23, 2025 [1][2] - The total number of valid repurchase applications for the "San Nuo Convertible Bonds" was reported as 0, indicating no bonds were sold back to the company [2][3] - The repurchase of the convertible bonds is not expected to significantly impact the company's financial status, capital structure, operating results, or cash flow [3] Group 2 - The company confirmed that the unrepurchased "San Nuo Convertible Bonds" will continue to be traded on the Shenzhen Stock Exchange [3] - The company has complied with relevant regulations and disclosed the necessary information regarding the bond repurchase process [1][2] - The board of directors of the company guarantees the accuracy and completeness of the information disclosed [1]